Pritelivir

Pritelivir
Names
Systematic IUPAC name
N-Methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-2-yl)phenyl]acetamide
Other names
AIC-316, BAY 57-1293, Hovilpri
Identifiers
3D model (JSmol)
ChemSpider
KEGG
UNII
  • InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25)
    Key: IVZKZONQVYTCKC-UHFFFAOYSA-N
  • InChI=1/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25)
    Key: IVZKZONQVYTCKC-UHFFFAOYAL
  • CN(C(=O)CC1=CC=C(C=C1)C2=CC=CC=N2)C3=NC(C)=C(S3)S(N)(=O)=O
Properties
C18H18N4O3S2
Molar mass 402.49 g·mol−1
Pharmacology
None
By mouth
Legal status
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Pritelivir, sold under the brand name Hovilpri, is an antiviral medication used for the treatment of herpes simplex virus infections. It is a herpes simplex virus helicase-primase inhibitor. It is used in the salt form pritelivir mesylate monohydrate. It is taken by mouth.

The most common adverse reactions include headache.

Pritelivir was approved for medical use in the United States in October 2026.

Medical use

Pritelivir is indicated in immunocompromised adults for the treatment of mucocutaneous lesions caused by herpes simplex virus infection that is refractory (with or without documented resistance) to treatment with acyclovir, valacyclovir, or famciclovir.

Adverse effects

The most common adverse reactions include headache.

Pharmacology

Mechanism of action

Pritelivir is an antiviral medication against herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2).

Pritelivir is a member of the helicase-primase inhibitors, a novel class of direct-acting antiviral medications acting specifically against HSV-1 and HSV-2. The medication acts through inhibition of the viral helicase primase complex, encoded by the UL5 (helicase), UL8 (scaffold protein) and UL52 (primase) genes, which is essential for HSV replication.

History

The efficacy of pritelivir was evaluated in a randomized, open-label, comparator-controlled, superiority trial (PRIOH-1 Phase III Trial, Part C; NCT03073967) in immunocompromised participants with mucocutaneous herpes simplex virus infection who did not respond to treatment with acyclovir, valacyclovir, or famciclovir. Participants received pritelivir or the trial investigator's choice of available treatments for up to 28 days until all mucocutaneous lesions healed, which was extended up to 42 days if lesions were improving but not completely healed after 28 days. A total of 101 immunocompromised adults were randomly assigned and treated with pritelivir or the investigator's choice of available treatments. Participants had a wide range of immunosuppressive clinical conditions, including one or more of the following: hematologic malignancy/disorder, hematopoietic stem-cell transplantation, HIV infection, autoimmune/inflammatory diseases, non-hematologic malignancies, or solid-organ transplantation.

Society and culture

Pritelivir was approved for medical use in the United States in October 2026. The US Food and Drug Administration granted the application for pritelivir priority review designation.

Names

Pritelivir is the international nonproprietary name.

Pritelivir is sold under the brand name Hovilpri.

References

  1. 1 2 3 4 5 6 7 https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/221154Orig1s000lbl.pdf
  2. 1 2 3 4 5 6 7 8 9 10 "FDA Approves Drug to Treat Lesions Caused by Herpes Simplex Virus". U.S. Food and Drug Administration (FDA). 9 October 2026. Retrieved 13 October 2026. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ↑ Biswas S, Jennens L, Field H (2007). "Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture". Archives of virology. 152 (8): 1489–500. doi:10.1007/s00705-007-0964-7. PMID 17404685. S2CID 23688945.
  4. ↑ Field H, Biswas S (February 2011). "Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus". Drug resistance updates. 14 (1): 45–51. doi:10.1016/j.drup.2010.11.002. PMID 21183396.
  5. ↑ Crute J, Tsurumi T, Zhu L, Weller S, Olivo P, Challberg M (April 1989). "Herpes simplex virus 1 helicase-primase: a complex of three herpes-encoded gene products". Proceedings of the National Academy of Sciences of the United States of America. 86 (7): 2186–2189. Bibcode:1989PNAS...86.2186C. doi:10.1073/pnas.86.7.2186. PMC 286876. PMID 2538835.
  6. ↑ World Health Organization (2012). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 68". WHO Drug Information. 26 (3). hdl:10665/109813.